WEBULL
WebtradeDownload

GE HealthCare (GEHC) Stock Price Faces Margin Pressure Despite Solid Q2 Growth

Simply Wall St · 1d ago

GE HealthCare Technologies walked into this report with the stock up over the past month and quarter, then gave back 2.7% today to close near US$69.94. That looks more like an emotional reaction than a verdict on collapse. Q2 brought solid imaging and diagnostics momentum, with revenue at US$5.3b and basic earnings per share of US$1.24. The real story is a squeeze on profitability, as trailing net profit margin has moved down to 9.3%. Today’s selling is the market voting on that margin pressure in real time.

Is GE HealthCare Technologies now a clear bargain on 15.9x P/E, or is the lower margin profile a warning that the stock deserves this discount? Compare the current share price against our valuation analysis for GE HealthCare Technologies

Q2 2026 Earnings Summary

  • Revenue (Q2 2026 vs Q2 2025): US$5,295m vs. US$5,007m (up about 5.7%)
  • Net Income, Excl. Extra Items (Q2 2026 vs Q2 2025): US$561m vs. US$486m (up about 15.4%)
  • Basic EPS (Q2 2026 vs Q2 2025): US$1.24 vs. US$1.06 (up about 16.4%)
  • Net Profit Margin, Trailing 12 Months: 9.3% vs. 11.2% one year ago (margin compressed)

Prefer clean charts instead of another wall of earnings numbers? See GE HealthCare Technologies' full visual breakdown of its recent profitability and margin profile in our company report for GE HealthCare Technologies.

NasdaqGS:GEHC Trailing 12-Month Revenue & Expenses Breakdown as at Jul 2026
NasdaqGS:GEHC Trailing 12-Month Revenue & Expenses Breakdown as at Jul 2026

Evaluating GE HealthCare’s High‑Margin Growth Story

The bullish story around GE HealthCare hinges on higher margin equipment, software and diagnostics gradually lifting earnings quality. Q2 gives some concrete proof points. Advanced Imaging Solutions sits at the center of that claim and delivered 5% organic revenue growth with a 90 bps EBIT margin improvement, supported by CT, MR and cardiovascular platforms that tie directly to the Photonova, MR and AI workflow narrative. Pharmaceutical Diagnostics also moved in the right direction, with 14.6% organic revenue growth and Flyrcado doses rising about 40% since April.

The recurring and software angle is starting to show through as well. Service revenue grew faster than product and the record US$23.9b backlog with an 11% orders increase suggests the equipment base that feeds future service and subscription income is expanding. These are early but tangible milestones for the bullish thesis on mix and margin quality.

Compare GE HealthCare Technologies’ internal progress on higher margin service and diagnostics growth with institutional expectations. See the consensus price target analysis for GE HealthCare Technologies to check how closely Wall Street targets line up with this earnings story.

GE HealthCare Bears Still Focused On Margin Friction

The cautious view on GE HealthCare says execution friction and cost pressure will cap margins and keep earnings progress modest. This quarter does not clear that bar. Adjusted EBIT margin dipped to 14.2%, which runs below the full year target range of 15.4% to 15.7%, so the promised expansion is still in front of you rather than in the bag. PCS turned EBIT negative, and management is only talking about stabilization and sequential improvement rather than a clean fix, which fits the concern that operational issues can drag on for several quarters.

Bears also worry that input cost inflation and PDx pricing pressure will offset mix benefits. Management flagged component and freight inflation and kept full year guidance unchanged instead of lifting it despite strong orders and backlog. That is another hint that cost and pricing risks remain very real in the GE HealthCare story.

Review whether GE HealthCare Technologies' margin friction and high debt are early warning signs or a deeper structural problem when you scan our risk analysis for GE HealthCare Technologies which shows 1 important warning sign.

Stay Ahead With GE HealthCare Insights

If the mix of margin pressure and backlog strength around GE HealthCare Technologies has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for an entry point that fits your plan. After you own the stock, use the Portfolio Command Center to cut through market noise and focus on the key developments that matter for your holdings. For a broader view on what other investors are seeing in GE HealthCare Technologies, tap into shared ideas and debate through the Community. This approach can help you identify potential catalysts and risks early so you can stay one step ahead of the market.

Seeking Alternatives Beyond GE HealthCare

Fresh ideas can move quickly once momentum builds. Spot potential breakouts and stocks still flying under the radar for now, before the crowd catches on. Get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.